Monthly Archives: October 2011

Public Exits and Virtual Biotechs – Dreams or Reality?

Here at the 10th Annual BIO Investor Forum, investors and CEOs are debating “all the options” for private companies. The first panel of the conference explored the backdoor entrance into public markets as chilly winds continue to blow through the latest IPO window. For the lunch plenary, panelists examined the option to go virtual and make capital efficiency a reality. Reverse Mergers It is no secret that the IPO market for biotechs has been tough. Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , ,

Reverse Mergers: A Company is Ready to Go Public, or it’s Not

Stock Ticker

The latest IPO window has stalled. There have been five IPO withdrawals since June and around 30 since 2005. Global macro events are threatening to completely shut it. Reverse mergers have become an increasingly popular option with eight transactions in the last year. Unfortunately, 47 percent of reverse mergers have decreased in value post-close since 2008. At the 2011 BIO Investor Forum, a panel of experts examined the current financing environment and what private executive Read More >

Business of Biotech  |  2 Comments  |  Email This Post
Tags: , , , ,

BioFlorida Conference: Here’s What You Missed

Isaac Ro, Goldman Sachs

As I mentioned last week, BIO President & CEO James C. Greenwood kicked-off  this week’s BioFlorida 14th Annual Conference with a keynote speech. Thanks to @BioFlorida2011 for tweeting some of his speech highlights. If you were not able to make it to Tampa for the conference, fear not, I’ve got you covered. Here’s a rundown of some of the things you missed: It’s All About Efficiency, Innovation and Globalization Goldman Sachs equity analyst Isaac Ro Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , ,

Bioenergy Business Outlook Survey Measures Industry Confidence

Biofuel Research

Biofuels Digests’ Bioenergy Business Outlook Survey, co-sponsored by BIO, is a quarterly indicator of business confidence, financial outlook and growth intentions. The results of the survey provide valuable insight into the mood of leaders in the bioenergy industry. More than a third of respondents each quarter identify themselves as chief executive or owner of their business. Nearly two-thirds of respondents identify themselves as directly involved in bioenergy production, either as producers, investors, business partners or Read More >

Biofuels & Climate Change  |  Leave a comment  |  Email This Post
Tags: , , , ,

BIO Investor Forum Company Snapshot: Protagonist Therapeutics

Protagonist

In our final Investor Forum Company Snapshot, we’ve profiled one of the Discovery Companies who will be presenting at the event. Protagonist Therapeutics shares their take on funding challenges and upcoming priorities, plus interesting facts about their company. Don’t miss their presentation first thing Tuesday morning! Company Snapshot What are the short-term and long-term priorities for your company? Protagonist is a peptide therapeutics based technology platform company. Short term priority:  Secure a second collaboration and Read More >

The One-on-One Compass  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,